Dr. Ebenezer Kio, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 397
Licensed in Illinois since 2024, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IN license 01066705A · IL license 036169262 (first issued 2024; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The University of Chicago Medical Center Chicago, IL
- St Mary Medical Center Inc Hobart, IN
- Franciscan Health Crown Point Crown Point, IN
- Franciscan Health Michigan City Michigan City, IN
- Uchicago Medicine Northwest Indiana Crown Point, IN
Medical groups
- University of Chicago (1,712 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 397
- Services billed
- 857
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 310 | 177 |
| Established patient office or other outpatient visit, 40-54 minutes | 195 | 105 |
| Established patient office or other outpatient visit, 20-29 minutes | 67 | 61 |
| New patient office or other outpatient visit, 60-74 minutes | 39 | 39 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 30 | 27 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 19 | 13 |
| New patient office or other outpatient visit, 45-59 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prochlorperazine Maleate Other prescribers in Mishawaka, IN | 28 |
| Anastrozole Other prescribers in Mishawaka, IN | 27 |
| Potassium Chloride Other prescribers in Mishawaka, IN | 25 |
| Brukinsa (zanubrutinib) | 24 |
| Ondansetron Odt (ondansetron) Other prescribers in Mishawaka, IN | 23 |
| Calcitriol Other prescribers in Mishawaka, IN | 22 |
| Dexamethasone Other prescribers in Mishawaka, IN | 17 |
| Betamethasone Diprop Augmented (betamethasone/propylene glyc) | 16 |
| Eliquis (apixaban) Other prescribers in Mishawaka, IN | 16 |
| Prednisone Other prescribers in Mishawaka, IN | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $8,466 in research payments for these studies, mostly to the institutions running them.
- A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors
Amgen Inc. - M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (…
AbbVie Inc. - Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Mirati Therapeutics, Inc. · Terminated · NCT03906071
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.